PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 Earnings Call Registration. You may access the live webcast of the conference call by using the following link: Nanox Q1 Earnings Webcast. The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations. About Nanox Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision. Contacts Media Contact:Ben ShannonICR WestwickeNanoxPR@icrinc.com Investor Contact:Mike CavanaughICR Westwickemike.cavanaugh@westwicke.com
Other News
Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today…
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
May 16, 2024 04:05 PM Eastern Daylight Time BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance […]
Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE for Ventricular Tachycardia Cryoablation System
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration […]
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
Cutting-edge tool analyzes data from cardiac remote monitoring devices to assess whether a patient is at high risk of experiencing worsening heart failure, enabling medical teams to intervene and avoid hospitalization. CAMBRIDGE, Mass., May 17, 2024 /PRNewswire/ — Implicity, a leader in…
Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software
Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space. With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging…
Philips presents study results at Heart Rhythm Annual Meeting demonstrating benefits of its AI-powered cardiac monitoring solutions
May 17, 2024
Element Science Appoints Lee Smith, Jr. as the Company’s First Head of Commercial
SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company’s first Head of Commercial. With nearly 20 years of successful leadership experience in sales, commercial operations, and customer success, Mr. Smith […]
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch
TEL AVIV, Israel & ZURICH, & NEW YORK–(BUSINESS WIRE)–SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (“SHL” or the “Company“), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it’s SmartHeart® membership program in the US. “The official launch marks a […]
EuroPCR 2024: Primary Outcomes from PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for Calcium Fragmentation in Moderate to Severe Calcified Coronary Artery Lesions
PARIS–(BUSINESS WIRE)–Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced that the PINNACLE I study evaluating the safety and performance of its LithiX™ Hertz Contact Intravascular Lithotripsy System (IVL) for treatment of moderate to severely calcified coronary artery lesions met its primary safety and […]
Recent
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging
Popular
- No commented posts yet